Xconomy

MAY 24, 2019

Patients, doctors, family members, and drug-price watchdogs continued to wait for the expected approval of Zolgensma , a Novartis (NYSE: NVS ) gene therapy for the rare inherited disease spinal muscular atrophy. Originally developed at a children’s hospital in Ohio , Zolgensma will be a litmus test for the nascent field.

Pricing 86

Pricing Marketing Develop Development 86

Xconomy

AUGUST 11, 2017

With President Trump holed up in New Jersey, rattling his saber at Kim Jong-un and Mitch McConnell and ignoring his own commission’s advice on the opioid crisis, there was still life sciences news from the nation’s capital.

Pricing 52

Pricing News Report Competition 52

socalTECH

FEBRUARY 16, 2010

For this morning's interview, we talked with Noah Auerhahn , President of San Diego-based Extrabux (www.extrabux.com), an online site focused on providing consumers with comparison shopping combined with discount offers. Did you have any prior background in this, and what were you two studying? Noah, thanks for the interview.

USC 207

USC CPC Sites Startup 207

Xconomy

SEPTEMBER 1, 2017

billion, the price Gilead Sciences is paying for Kite Pharma and its cancer-fighting cell therapy pipeline. The far-out idea of reprogramming a patient’s immune cells to fight cancer, known as CAR-T, entered the mainstream this week, and two numbers highlight the tale. The first is $11.9

Pricing 74

Pricing Ideas San Diego Study 74

Xconomy

APRIL 20, 2018

The price of drugs is certainly on a lot of minds these days, including the mind of President Trump, as he reportedly will make a. While pembrolizumab notched the headline-grabbing data, others are also working to develop options for various subsets of patients. Who will be able to afford all these options?

Pricing 52

Pricing News Report Develop 52

Xconomy

SEPTEMBER 16, 2016

New documents came to light that showed the sugar industry paid for studies downplaying the ties between sugar and heart disease. Meanwhile, there was yet another twist in the ongoing Duchenne muscular dystrophy drama, more biotech buyouts, new startups, and the filing of a long anticipated IPO. .

Research 40

Research Pricing News Report 40

Xconomy

AUGUST 30, 2019

You might be camping, barbecuing, or sleeping on Monday. It’s Labor Day, after all. But in Paris, this cardiologist will be in a conference center, walking an audience through a slide deck packed with Phase 3 data for a new cholesterol-lowering drug, inclisiran. Inclisiran’s owner, the Medicines Co.,

Slides 80

Slides Conference Venture Capital San Diego 80

Xconomy

NOVEMBER 4, 2016

The Mayo Clinic cardiologist behind the report published a study earlier this year about long QT misdiagnosis leading to improper defibrillator implants. Its owner Pfizer (NYSE: PFE ) shelved it this week , citing poor Phase 3 data and pricing pressures on the two approved PCSK9 drugs. Pfizer also reported worse-than-expected earnings.

Research 40

Research Report Pricing Journal 40

Xconomy

JANUARY 25, 2019

In a week of big personnel moves, none was more surprising than Editas Medicine CEO Katrine Bosley’s departure.

Guide 63

Guide Patents Startup Develop 63

Xconomy

JUNE 30, 2017

There is no Obamacare replacement, at least not as of this writing. The Senate Republicans are fractured, with a handful of conservatives and moderates each giving a cold shoulder to their chamber’s version of healthcare reform, the Better Care Reconciliation Act.

Writing 56

Writing Report Artificial Inteligence San Diego 56

Xconomy

SEPTEMBER 15, 2017

It was a week of realignments. President Trump, who used to be known as “The Donald” but now goes by “ Amnesty Don ,” kept up the parlay-voo with his new friends Chuck and Nancy. Martin Shkreli, who was once known— and still is!

Marketing 45

Marketing Venture Capital San Diego Study 45